Argenica Therapeutics Ltd has released a press release.
Argenica to Progress Clinical Development in TBI
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Update on Investigational New Drug Application
- New US Patent for Surgical Stroke
- Last Patient Dosed in Phase 2 Stroke Trial
- Updated - Main TBI Injury Study Annoucement
- ARG-007 Shows Significant Neuroprotection in Main TBI Study
Later from Argenica Therapeutics
- Argenica Awarded Federal Government Funding
- Argenica Receives IND Feedback From FDA
- Appendix 4E & Annual Report to 30 June 2025
- Trading Halt
- Topline Phase 2 Trial Results of ARG-007 in AIS Patients
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics